Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 8/20 | 0.47 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | ACSL1 | P33121 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10186294 | 0.92 | HTR1A (0.48) | DGAT1RAB9ANPC1HDAC1 | |
| SCHEMBL10186292 | 0.88 | RAB9A (0.47) | DGAT1RAB9ANPC1 | |
| SCHEMBL10185532 | 0.87 | DGAT1 (0.57) | DGAT1RAB9AHDAC3HDAC1 | |
| SCHEMBL662996 | 0.87 | DGAT1 (0.57) | DGAT1RAB9AHDAC3HDAC1 | |
| SCHEMBL662997 | 0.87 | DGAT1 (0.57) | DGAT1RAB9AHDAC3HDAC1 | |
| SCHEMBL10186300 | 0.83 | DGAT1 (0.50) | DGAT1RAB9ANPC1HDAC3HDAC1 | |
| SCHEMBL10185116 | 0.83 | DGAT1 (0.47) | DGAT1RAB9ANPC1CHRNA7 | |
| SCHEMBL10184403 | 0.83 | DGAT1 (0.54) | DGAT1 | |
| SCHEMBL10184911 | 0.82 | DGAT1 (0.49) | DGAT1RAB9ANPC1HDAC3HDAC1 | |
| SCHEMBL10185798 | 0.82 | DGAT1 (0.52) | DGAT1RAB9AHDAC3HDAC1ACSL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-23 | — | — | US | disclosed |
| WO-2010122968-A1 | DIACYLETHYLENEDIAMINE COMPOUND | アステラス製薬株式会社 (JP) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | DGAT1, DGAT2, DIMT1 | DGAT1 1/4885EGLN1 2857/4885RAB9A 1660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.